Oppositional Defiant Disorder | Defiant Teenager | Defiant Kid | ADHD

Back to ADHD News List

Shire Announces Once Daily Guanfacine Extended Release Data In ADHD Patients Aged 6 To 17 Years

Shire plc (Nasdaq: SHPGY, LSE: SHP, TSX: SHQ) has announced that once-daily doses of the investigational medication guanfacine extended release (GXR, also referred to as SPD503), a selective alpha-2A-adrenoceptor agonist, significantly improved symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 17 years when used as a monotherapy. The phase III trial results were presented at the 2006 U.S. Psychiatric & Mental Health Congress (USPMHC) annual meeting. [click link for full article]

Source: http://www.medicalnewstoday.com/sections/adhd/

 

In schools, treatment plans are often poorly integrated. In addition, there are few special education funds directed specifically for ADHD
 

This page is about Attention deficit hyperactivity disorder (ADHD)

Oppositional Defiant Disorder | Defiant Teenager | Defiant Kid | ADHD